Brainomix has unveiled compelling results from its collaboration with Argenica Therapeutics, showcasing the efficacy of ARG-007, a neuroprotective agent for severe acute ischemic stroke. Utilizing the Brainomix 360 Stroke platform, an FDA-cleared and CE-marked AI imaging tool, the analysis revealed statistically significant improvements in neurological function and disability outcomes among patients treated with ARG-007 compared to placebo, particularly in those with larger infarcts at baseline.
This breakthrough addresses a critical issue in stroke clinical trials: the variability in baseline assessments that can obscure treatment effects. By leveraging standardized AI imaging biomarkers, Brainomix 360 Stroke provided objective measurements that enhanced patient stratification, thereby revealing previously hidden treatment benefits. Dr. Michalis Papadakis, CEO of Brainomix, emphasized the importance of precision imaging in clinical trial design, which can accelerate the development of effective therapies.
Dr. Liz Dallimore, CEO of Argenica Therapeutics, echoed this sentiment, noting that the insights gained from Brainomix’s analysis will inform the design of future studies, aligning with precision medicine principles. The integration of AI in clinical trials not only enhances the clarity of treatment effects but also optimizes patient selection based on objectively assessed brain injury, ultimately aiming for improved recovery outcomes.
Use the database as your supply chain compass →
